摘要:
An active device array mother substrate including a substrate, a plurality of active device arrays, a plurality of common bus lines, at least one first transparent conductive pattern layer, and at least one second transparent conductive pattern layer is provided. The substrate has a plurality of predetermined areas, and the active device arrays are respectively disposed in the predetermined areas. The common bus lines are respectively disposed in the predetermined areas to surround the active device arrays. The first transparent conductive pattern layer is connected or coupled between adjacent two common bus lines. The second transparent conductive pattern layer is extended to the adjacent predetermined area to be connected or coupled to the adjacent common bus line.
摘要:
An active device array mother substrate including a substrate, a plurality of active device arrays, a plurality of common bus lines, at least one first transparent conductive pattern layer, and at least one second transparent conductive pattern layer is provided. The substrate has a plurality of predetermined areas, and the active device arrays are respectively disposed in the predetermined areas. The common bus lines are respectively disposed in the predetermined areas to surround the active device arrays. The first transparent conductive pattern layer is connected or coupled between adjacent two common bus lines. The second transparent conductive pattern layer is extended to the adjacent predetermined area to be connected or coupled to the adjacent common bus line.
摘要:
A preparation of aryl carbamates can be achieved readily by carbonylation of an aromatic polyamine compound with diphenyl carbonate (DPC) using a combination of an organic acid and a tertiary amine as a catalyst. Aryl carbamate can be converted into 4,4′-diphenylmethane diisocyanate (MDI) by heating it at about 200 to about 230° C. in a non-polar solvent containing inhibitor such as benzoyl chloride. In another application, trans-ureation of biscarbamates with an amine or mixed amines is found to be extremely facile in a polar solvent such as dimethyl sulfoxide (DMSO) and tetramethylene sulfone (TMS) in absence of any catalyst to make polyurea polymers of high molecular weights. Thus, efficient green-chemistry processes based on biscarbamates in making isocyanate products as well as urea prepolymers, urea elastomers and urea plastics have been developed in all in excellent yields without using reactive phosgene or 4,4′-diphenylmethane diisocyanate separately in the trans-ureation polymerizations.
摘要:
This invention provides a process for producing a radioactive arsenic-containing compound, comprising the steps of: (i) subjecting an arsenic-containing compound to a neutron irradiation treatment, said arsenic-containing compound being selected from a group consisting of As2O3, As2S3, As2S2, and a combination thereof, such that the arsenic element contained in the arsenic-containing compound is converted to a radioactive arsenic isotope; and (ii) recovering the resultant product from step (i). This invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the radioactive arsenic-containing compound and a pharmaceutically acceptable carrier. The pharmaceutical composition can be used in the treatment of tumors/cancers such as hematological malignancies and solid tumors.
摘要:
This invention provides a process for producing a radioactive arsenic-containing compound, comprising the steps of: (i) subjecting an arsenic-containing compound to a neutron irradiation treatment, said arsenic-containing compound being selected from a group consisting of As2O3, As2S3, As2S2, and a combination thereof, such that the arsenic element contained in the arsenic-containing compound is converted to a radioactive arsenic isotope; and (ii) recovering the resultant product from step (i).This invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the radioactive arsenic-containing compound and a pharmaceutically acceptable carrier. The pharmaceutical composition can be used in the treatment of tumors/cancers such as hematological malignancies and solid tumors.
摘要:
A preparation of aryl carbamates can be achieved readily by carbonylation of an aromatic polyamine compound with diphenyl carbonate (DPC) using a combination of an organic acid and a tertiary amine as a catalyst. Aryl carbamate can be converted into 4,4′-diphenylmethane diisocyanate (MDI) by heating it at about 200 to about 230° C. in a non-polar solvent containing inhibitor such as benzoyl chloride. In another application, trans-ureation of biscarbamates with an amine or mixed amines is found to be extremely facile in a polar solvent such as dimethyl sulfoxide (DMSO) and tetramethylene sulfone (TMS) in absence of any catalyst to make polyurea polymers of high molecular weights. Thus, efficient green-chemistry processes based on biscarbamates in making isocyanate products as well as urea prepolymers, urea elastomers and urea plastics have been developed in all in excellent yields without using reactive phosgene or 4,4′-diphenylmethane diisocyanate separately in the trans-ureation polymerizations.
摘要:
A composite structure of a composite substrate and a plastic material is provided. The composite structure is fabricated by a method including the steps of: preparing a plurality of fiber layers weaved in different directions and laminating the fiber layers to configure a stack; soaking the stack in a resin, and drying the soaked stack to obtain a composite substrate; conducting a compression molding process to the composite substrate to achieve a predetermined shape; putting the compression molded composite substrate in a mold of a plastic injection molding machine; injecting a melting plastic material obtained from plastic particles melted by an extrusion machine into the mold, for combining with the composite substrate; and water cooling for hardening the combination, thus achieving a product of the composite structure.
摘要:
The present invention provides a method of treating mammals having pancreatic cancer by administering a liposomal doxorubicin pharmaceutical composition, and a process of manufacturing the composition.